1613404-76-4

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethoxy)phenyl)-1H-benzo[d]imidazole hydrochloride is used as a potential pharmaceutical agent for its complex molecular structure that may allow for interactions with biological systems. The specific application reason is yet to be determined, but its structure indicates potential therapeutic uses in medicine.
Used in Research and Development:
In the field of research and development, (S)-1-benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethoxy)phenyl)-1H-benzo[d]imidazole hydrochloride serves as a subject for further investigation into its therapeutic potential and possible applications in pharmacology. (S)-1-benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethoxy)phenyl)-1H-benzo[d]imidazole hydrochloride's unique structure may lead to the discovery of new drug candidates or therapeutic approaches.

Upstream product

• 1440754-99-3 (S)-tert-butyl 4-(2-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-nitrophenylamino)ethyl)piperidine-1-carboxylate 
• 1440754-72-2 (S)-tert-butyl 4-(2-hydroxy-1-(2-nitrophenylamino) ethyl)piperidine-1-carboxylate 
• 1440754-66-4 tert-butyl 4-((S)-1-azido-2-oxo-2-((S)-2-oxo-4-phenyloxazolidin-3-yl)ethyl)piperidine-1-carboxylate 
• 1613404-75-3 C₂₁H₂₈N₂O₅ 
• 10206-01-6 4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenol 
• 425365-62-4 2-(4-(allyloxy)phenyl)-1H-benzo[d]imidazole 
• 95-54-5 1,2-diamino-benzene 
• 40663-68-1 4-(2-propenyloxy)benzaldehyde 
• 1440755-05-4 (S)-tert-butyl-4-(2-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate 
• 1440754-78-8 C₁₂H₂₂N₄O₃ 
• 100-39-0 benzyl bromide 
• 1440753-42-3 2-(4-(allyloxy)phenyl)-1-benzyl-1H-benzo[d]imidazole 

Downstream Products

• 1613404-97-9 C₄₃H₃₉N₅O₂ 

Relevant academic research and scientific papers

Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site

K-Ras is one of the most frequently mutated signal transducing human oncogenes. Ras signaling activity requires correct cellular localization of the GTPase. The spatial organization of K-Ras is controlled by the prenyl binding protein PDEδ, which enhances Ras diffusion in the cytosol. Inhibition of the Ras-PDEδ interaction by small molecules impairs Ras localization and signaling. Here we describe in detail the identification and structure guided development of Ras-PDEδ inhibitors targeting the farnesyl binding pocket of PDEδ with nanomolar affinity. We report kinetic data that characterize the binding of the most potent small molecule ligands to PDEδ and prove their binding to endogenous PDEδ in cell lysates. The PDEδ inhibitors provide promising starting points for the establishment of new drug discovery programs aimed at cancers harboring oncogenic K-Ras.

BENZIMIDAZOLES FOR THE TREATMENT OF CANCER

The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.